From the beginning we have stated that the growth we are seeing in the CGM market is just the tip of the iceberg. That usage among patients with diabetes is what can be seen above the water line. All along we have stated that there is a much larger market which will drive CGM adoption among non-diabetics will transform this market. Yesterday we moved one step closer to seeing this happen as Abbott has teamed up with Atlanta based SuperSapiens to launch the Libre Sense.
For the moment this system which has received CE approval in Europe is designed . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.